Compare · MGRX vs PGNY
MGRX vs PGNY
Side-by-side comparison of Mangoceuticals Inc. (MGRX) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRX and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $1.98B, about 237.0x MGRX ($8.4M).
- Over the past year, MGRX is down 78.5% and PGNY is up 14.2% - PGNY leads by 92.6 points.
- MGRX has been more active in the news (12 items in the past 4 weeks vs 6 for PGNY).
- PGNY has more recent analyst coverage (25 ratings vs 0 for MGRX).
- Company
- Mangoceuticals Inc.
- Progyny Inc.
- Price
- $0.39+2.51%
- $25.84+1.55%
- Market cap
- $8.4M
- $1.98B
- 1M return
- -31.28%
- -18.21%
- 1Y return
- -78.48%
- +14.16%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 12
- 6
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest MGRX
- Mangoceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mangoceuticals Inc.
- SEC Form 425 filed by Mangoceuticals Inc.
- Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
- Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
- Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
- Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
- SEC Form 425 filed by Mangoceuticals Inc.
Latest PGNY
- Wells Fargo initiated coverage on Progyny with a new price target
- Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
- SEC Form 10-Q filed by Progyny Inc.
- Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Progyny, Inc. Announces Second Quarter 2026 Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- Progyny downgraded by Barclays with a new price target
- Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
- Chief Operating Officer Cummings Melissa B covered exercise/tax liability with 1,193 shares and sold $70,910 worth of shares (2,244 units at $31.60) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 69,934 units (SEC Form 4) to satisfy withholding obligation
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,828 units (SEC Form 4) to satisfy withholding obligation